GSK (GSK) Competitors

AstraZeneca (LON:AZN) and GSK (LON:GSK) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, media sentiment, risk, valuation, community ranking and earnings.

Do analysts rate AZN or GSK?

AstraZeneca currently has a consensus target price of £104.12, suggesting a potential downside of 0.95%. GSK has a consensus target price of GBX 1,805.83, suggesting a potential upside of 31.48%. Given GSK's stronger consensus rating and higher possible upside, analysts clearly believe GSK is more favorable than AstraZeneca.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AstraZeneca	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56
GSK	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Which has more risk and volatility, AZN or GSK?

AstraZeneca has a beta of 0.17, suggesting that its share price is 83% less volatile than the S&P 500. Comparatively, GSK has a beta of 0.31, suggesting that its share price is 69% less volatile than the S&P 500.

Do institutionals & insiders believe in AZN or GSK?

51.0% of AstraZeneca shares are held by institutional investors. Comparatively, 45.3% of GSK shares are held by institutional investors. 0.0% of AstraZeneca shares are held by company insiders. Comparatively, 1.6% of GSK shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Is AZN or GSK a better dividend stock?

AstraZeneca pays an annual dividend of GBX 234 per share and has a dividend yield of 2.2%. GSK pays an annual dividend of GBX 60 per share and has a dividend yield of 4.4%. AstraZeneca pays out 7,428.6% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. GSK pays out 5,309.7% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. GSK is clearly the better dividend stock, given its higher yield and lower payout ratio.

Does the media prefer AZN or GSK?

In the previous week, GSK had 1 more articles in the media than AstraZeneca. MarketBeat recorded 1 mentions for GSK and 0 mentions for AstraZeneca. GSK's average media sentiment score of 0.11 beat AstraZeneca's score of 0.00 indicating that GSK is being referred to more favorably in the news media.

Company	Overall Sentiment
AstraZeneca	Neutral
GSK	Neutral

Is AZN or GSK more profitable?

AstraZeneca has a net margin of 13.11% compared to GSK's net margin of 12.83%. GSK's return on equity of 33.30% beat AstraZeneca's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AstraZeneca	13.11%	16.74%	7.68%
GSK	12.83%	33.30%	9.56%

Does the MarketBeat Community believe in AZN or GSK?

AstraZeneca received 768 more outperform votes than GSK when rated by MarketBeat users. Likewise, 63.70% of users gave AstraZeneca an outperform vote while only 50.42% of users gave GSK an outperform vote.

Company	Underperform	Outperform
AstraZeneca	Outperform Votes 1858 63.70%	Underperform Votes 1059 36.30%
GSK	Outperform Votes 1090 50.42%	Underperform Votes 1072 49.58%

Which has better valuation and earnings, AZN or GSK?

AstraZeneca has higher revenue and earnings than GSK. GSK is trading at a lower price-to-earnings ratio than AstraZeneca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AstraZeneca	£49.13B	3.32	£6.44B	£3.15	3,337.14
GSK	£31.45B	1.78	£4.03B	£1.13	1,215.49

Summary

AstraZeneca and GSK tied by winning 10 of the 20 factors compared between the two stocks.